Physician profile
Anna Walsh
NPI 1205491461
$3,880.56
in general payments reported to CMS, 2019-2025
13 companies · $1,295 in 2025
The $1,295 reported for 2025 was more than what 82% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $486 · 2022: $724 · 2023: $1,219 · 2024: $156 · 2025: $1,295.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,670.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,669.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,556.09 | 2021-2025 | Hydrus Microstent, Argos, Clareon |
| Abbvie INC. | $583.56 | 2022-2025 | Durysta, Ozurdex, Lumigan |
| Glaukos Corporation | $396.41 | 2023-2025 | Photrexa Viscous and Photrexa, Kxl System (Not Refurbished) |
| Bausch & Lomb Americas INC. | $308.58 | 2022-2025 | Vyzulta, Lotemax Sm, Xiidra |
| Ocular Therapeutix, INC. | $288.24 | 2025 | Dextenza |
| Sight Sciences, INC. | $155.11 | 2023 | Omni Surgical System |
| Allergan, INC. | $138.19 | 2021-2022 | |
| Tarsus Pharmaceuticals, INC. | $131.40 | 2025 | Xdemvy |
| Biotissue Holdings INC. | $125.00 | 2025 | |
| Horizon Therapeutics Plc | $64.94 | 2021 | |
| Amgen INC. | $59.98 | 2025 | Tepezza |
| Thea Pharma INC. | $57.20 | 2024-2025 | Iyuzeh |
| Immunocore Limited | $15.86 | 2025 | Kimmtrak |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anna Walsh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.